RxDoctor Payments Data

Lyudmila Emag, NP

Adult Health · Brooklyn, NYNPI 1619126588

Payments from drug & device makers

$3,384in general payments, 2019–2025

Across 118 payments — averaging $28.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$1K
  • Antares Pharma, Inc.$454
  • Astellas Pharma US Inc$417
  • Urovant Sciences Inc$413
  • Pfizer$191
  • Arcutis Biotherapeutics, Inc.$161
  • plus $708 from 14 others

What the payments were for

  • Food & beverage$3,08891%
  • Education$2969%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,384 in reported general payments places this provider in the 85th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$50,414
Medicare patients
332
Services billed
1,138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron600$310,271
XtandiEnzalutamide15$209,944
MyrbetriqMirabegron123$59,297
Estradiol770$49,472
LinzessLinaclotide39$23,727
Tamsulosin Hcl1,341$16,282
PremarinEstrogens, Conjugated28$11,940
CialisTadalafil33$11,443
TrulicityDulaglutide12$10,819
RapafloSilodosin29$8,327
Finasteride654$6,268
TradjentaLinagliptin12$5,812
Tadalafil36$5,055
Mirabegron ErMirabegron12$4,285
Alfuzosin Hcl ErAlfuzosin Hcl228$3,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$1,039$310,271600 claims
Astellas Pharma US IncXtandi, Myrbetriq$417$269,241138 claims
AbbVieLinzess$94$23,72739 claims
PfizerPremarin$191$11,94028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,828 adult health providers in New York.

Other adult health in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →